Brokerages Set LivaNova PLC (NASDAQ:LIVN) Target Price at $69.17

LivaNova PLC (NASDAQ:LIVN) has been assigned a consensus rating of “Buy” from the seven brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $69.17.

Several equities analysts recently commented on LIVN shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a research report on Tuesday, January 28th. Robert W. Baird increased their price objective on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Mizuho decreased their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. Finally, StockNews.com raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 14th.

LivaNova Stock Down 1.1 %

NASDAQ:LIVN opened at $47.44 on Friday. LivaNova has a fifty-two week low of $43.15 and a fifty-two week high of $64.47. The stock has a market capitalization of $2.58 billion, a P/E ratio of 112.95 and a beta of 1.00. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The company’s 50-day simple moving average is $47.95 and its 200-day simple moving average is $49.54.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the transaction, the director now directly owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.27% of the stock is currently owned by insiders.

Hedge Funds Weigh In On LivaNova

A number of institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. raised its position in LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after buying an additional 219 shares during the last quarter. Summit Investment Advisors Inc. grew its stake in shares of LivaNova by 1.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company’s stock worth $780,000 after purchasing an additional 289 shares during the period. Atria Investments Inc grew its stake in shares of LivaNova by 6.2% during the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock worth $297,000 after purchasing an additional 331 shares during the period. State of Alaska Department of Revenue grew its stake in shares of LivaNova by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after purchasing an additional 425 shares during the period. Finally, Xponance Inc. grew its stake in shares of LivaNova by 6.1% during the 4th quarter. Xponance Inc. now owns 7,762 shares of the company’s stock worth $359,000 after purchasing an additional 445 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.